Drug
Oca
Oca: highest development phase Phase 2/3, developed by Intercept Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Intercept Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| OCA NCT06121375 | Phase 2/3 | Biliary Atresia |
| OCA 0.1mg NCT05321524 | Phase 2 | Biliary Atresia |
| OCA 5 mg NCT01933503 | Phase 1 | Healthy |
| OCA 10 mg NCT01914562 | Phase 1 | Healthy |
Latest
No recent events.
Follow Oca on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.